24/7 Patient Assistance: 760-405-8205

Adel Kardosh, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Adel Kardosh graduated from the Keck School of Medicine of USC and completed his residency program at the University of Southern California. Then, he did a fellowship at the Stanford University. He is specialized in Medical Oncology and board certified in Internal Medicine and Oncology. Dr. Kardosh has been in practice for more than 3 years and is affiliated with the LAC-USC Medical Center. During his career, he has also contributed to several research publications.

  • Education & Training


    Keck of USC

    Medical School


    University of Southern California - LAC+USC Medical Center



    Stanford University


  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    LAC - USC Medical Center

    Languages: English/Spanish

    (323) 409-1000

    2051 Marengo St.

    Los Angeles, California 90033

    Read More
  • Publications & Memberships

    Dr. Adel Kardosh has contributed to 3 publications.

    Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

    Volz, N. B.,Stintzing, S.,Zhang, W.,Yang, D.,Ning, Y.,Wakatsuki, T.,El-Khoueiry, R. E.,Li, J. E.,Kardosh, A.,Loupakis, F.,Cremolini, C.,Falcone, A.,Scherer, S. J.,Lenz...; Pharmacogenomics J.. 2014 Jul 30.

    See more >>

    Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature.

    Virrey, J. J., Liu, Z., Cho, H. Y., Kardosh, A., Golden, E. B., Louie, S. G., Gaffney, K. J., Petasis, N. A., Schönthal, A. H., Chen, T. C., Hofman, F. M.; Mol Cancer Ther. 2010 Mar.

    See more >>

    Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

    Golden, E. B., Lam, P. Y., Kardosh, A., Gaffney, K. J., Cadenas, E., Louie, S. G., Petasis, N. A., Chen, T. C., Schönthal, A. H.; Blood. 2009 Feb 05.

    See more >>